<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338373</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01</org_study_id>
    <nct_id>NCT04338373</nct_id>
  </id_info>
  <brief_title>Effectiveness of 0.01% Atropine Sulfate Solution in Controlling of Myopia Progression in Children</brief_title>
  <official_title>Open Prospective With Historical Control Clinical Study of 0.01 % Atropine Sulfate Effectiveness in Controlling of Myopia Progression in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The V.P. Vyhodcev Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The V.P. Vyhodcev Eye Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing number of myopic children and significant complications of high myopia enhance the
      necessity of effective control strategy. Instillations of low-dose atropine have been shown
      to reduce myopia progression in Asian populations but its effect in non-Asian populations is
      still unclear. This open prospective study with historical control is designed to investigate
      if 0.01% atropine can reduce myopia progression in Russian children, taking into account a
      change of difference between manifest and cycloplegic refraction, as well as, myopia
      progression rate at the time of recruitment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to test the following hypotheses:

        -  0.01% atropine one drop nightly is safe and with no significant side effects.

        -  nightly instillations of 0.01% atropine does not influence tear production.

        -  0.01% atropine one drop nightly reduces the progression of childhood myopia in Russian
           children.

        -  nightly instillations of 0.01% atropine decreases the manifest refraction and,
           consequently, difference between manifest and cycloplegic refractions.

        -  effectiveness of 0.01% atropine depends on the age and myopia progression rate at the
           time the therapy was started.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2020</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open prospective clinical trial with historical control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in axial length</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Change in axial length elongation from baseline to 12 months, as measured using IOLMaster, compared with historical data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in myopic progression rate</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Change in myopic progression rate measured as the difference between cycloplegic refraction from baseline to 12 months, compared with historical data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in difference between manifest and cycloplegic refractions</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>change in difference between manifest and cycloplegic (tropicamide 0.5%) refractions, measured with autorefractometer, compared with historical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in positive relative accommodation</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>change in positive relative accommodation, measured in maximal spectacles correction by using concave lenses until the image blurs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tear production</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>result of Schirmer I test</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.01% Atropine Sulfate solution in &quot;Comfort Drops&quot;, nightly instillations to both eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>0.01% Atropine sulfate solution in &quot;Comfort Drops&quot; (&quot;AVIZOR S.A.&quot;, Spain)</intervention_name>
    <description>nightly instillations of 0.01% Atropine sulfate solution in &quot;Comfort Drops&quot; (&quot;AVIZOR S.A.&quot;, Spain) in both eyes for 12 months</description>
    <arm_group_label>experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  myopia progression rate of 0.5D or more per year;

          -  myopia with astigmatism of 1.0D or less;

          -  axial length and cycloplegic refraction data obtained 6 months before recruiting or
             earlier

          -  signed informed consent.

        Exclusion Criteria:

          -  congenital myopia;

          -  onset of myopia at 6 years old or earlier;

          -  allergic reactions to any eye drops in anamnesis;

          -  concomitant eye disorders, including strabismus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The V.P. Vyhodcev Eye Hospital</name>
      <address>
        <city>Omsk</city>
        <zip>644024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daria S Afanasyeva, MD, PhD</last_name>
      <phone>+79835279729</phone>
      <phone_ext>+79852731785</phone_ext>
      <email>ada-tomsk@yandex.ru</email>
    </contact>
    <contact_backup>
      <last_name>Konstantin S Shchukin, MD</last_name>
      <phone>+79236789231</phone>
      <phone_ext>Afanasyeva</phone_ext>
      <email>lek.okob@inbox.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Daria S Afanasyeva, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anara H Abdrahmanova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 4, 2020</study_first_submitted>
  <study_first_submitted_qc>April 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The V.P. Vyhodcev Eye Hospital</investigator_affiliation>
    <investigator_full_name>Daria Afanasyeva</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>myopia</keyword>
  <keyword>low dose atropine</keyword>
  <keyword>progressive myopia</keyword>
  <keyword>atropine in non-asian population</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

